Google-backed Isomorphic raises $2.1 billion to scale AI-driven drug discovery

Isomorphic Labs raised $2.1 billion in its latest funding round, led by existing investor Thrive Capital. The capital infusion underscores strong investor confidence in AI-driven drug discovery and provides substantial resources to advance development. The news is positive for the company and supportive for the broader AI and biotech venture landscape.

Analysis

Isomorphic Labs raised $2.1 billion in its latest funding round, led by existing investor Thrive Capital. The capital infusion underscores strong investor confidence in AI-driven drug discovery and provides substantial resources to advance development. The news is positive for the company and supportive for the broader AI and biotech venture landscape.